Ocrelizumab injection for relapsing-remitting multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how well the injected form of ocrelizumab works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday care. It aims to understand the treatment's effects and side effects outside of a clinical trial setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- Your doctor has decided to start you on ocrelizumab as an injection under the skin (subcutaneous), as part of your normal care.
- You are willing to fill out a short questionnaire about your symptoms and quality of life.
- You have not been treated with rituximab before (a similar drug).
- You are not currently participating in another clinical study for multiple sclerosis treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injectable medication called ocrelizumab for children and teenagers with relapsing-remitting multiple sclerosis. The goal is to see if it is safe and how well it works to control the disease.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This trial looks at two medicines, rituximab and ocrelizumab, in the blood of people with multiple sclerosis. It only includes people who are already in another study called OVERLORD-MS and can give blood samples on a schedule.
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
Hear when a new Relapsing-Remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.